Here are three things to know:
1. Cohere is indicated for use with autograft and/or allograft in skeletally mature patients for thoracolumbar pathologies, such as degenerative disc disease, degenerative spondylolisthesis and degenerative scoliosis.
2. Cohere XLIF is designed to allow early incorporation of bone into the interbody spacer to prevent expulsion and promote fusion.
3. NuVasive expects to commercially launch Cohere XLIF in the U.S. in second quarter of 2019.
More articles on surface technology:
Spinal Elements earns FDA clearance for titanium surface coating
Titan Spine completes funding round: 3 things to know
Additive manufacturing company introduces new 3D-printed PEEK application — 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.